MedTrace Logo

Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease

NCT02231320 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 236

Last updated 2014-09-04

No results posted yet for this study

Summary

New perceptions about handling and patient satisfaction of the everyday use of Berodual® Respimat® in patients with chronic obstructive lung disease (COLD). Moreover, further knowledge should be attained about the tolerability of Berodual® Respimat®

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Berodual® Respimat® - inhaler

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2006-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02231320 on ClinicalTrials.gov